주 메뉴 바로가기 본문 바로가기 하단 바로가기

Celltrion

gnb메뉴보기

ENG

Gnb 메뉴 닫기

Pipeline

We look for ways to promote health and happiness for all

Antibody Biosimilars

Celltrion will continue to blaze new trails and discover new opportunities.
Project INN Original Major Indications Status Clinical Info
CT-P39 Omalizumab XOLAIR® Asthma, Urticaria Phase3 외부링크연결
CT-P41 Denosumab

PROLIA®

 Osteoporosis, Bone Loss Phase3 외부링크연결
CT-P43 Ustekinumab

STELARA

 Psoriasis, Crohn's disease, Ulcerative colitis Phase3
CT-P42 Aflibercept

EYLEA

 Diabetic Macular Edema Phase3 외부링크연결
CT-P47 Tocilizumab

ACTEMRA

 Rheumatoid arthritis Phase1 외부링크연결
  • * Registered trademarks of reference products
  • XOLAIR® is a registered trademark of NOVARTIS
  • AVASTIN® is a registered trademark of GENENTECH
  • PROLIA® is a registered trademark of AMGEN
  • STELARA® is a registered trademark of JANSSEN
  • EYLEA® is a registered trademark of REGENERON and BAYER
  • ACTEMRA® is a registered trademark of CHUGAI SEIYAKU

New Antibodies

Celltrion will continue to blaze new trails and discover new opportunities.
Project Indications Status Clinical Info
CT-P27 Pandemic·Seasonal influenza Phase2

IMDs

Celltrion will continue to blaze new trails and discover new opportunities.
Project Indications Status Clinical Info
CT-G20 Cardiomyopathy Phase1